Abstract
Studies demonstrating that accumulation and aggregation of the amyloid β protein (Aβ) within the brain is likely to cause Alzheimer's disease (AD) have provided the rationale for therapeutic strategies aimed at influencing Aβ production, aggregation and clearance. γ-secretase catalyzes the final cleavage that releases the Aβ from its precursor; therefore, it is a potential therapeutic target for the treatment of AD. Recent data show that the polytopic membrane proteins presenilin 1 and presenilin 2 are either catalytic components or essential co-factors of a membrane-bound proteolytic complex that possesses γ-secretase activity. Although recent findings demonstrating that γ-secretase inhibitors bind directly to presenilins (PSs) further support a catalytic role for PSs in γ-secretase cleavage, additional studies are still needed to clarify the role of PSs in γ-secretase cleavage and the use of targeting PSs to reduce Aβ production.
Original language | English (US) |
---|---|
Pages (from-to) | 264-269 |
Number of pages | 6 |
Journal | Trends in Molecular Medicine |
Volume | 7 |
Issue number | 6 |
DOIs | |
State | Published - 2001 |
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology